←
Patrick Kidger1,317 posts
Patrick Kidger avatar

Patrick Kidger

@PatrickKidger

🚀Curing uncured diseases 🧪Bio+AI geek: kidger.site/thoughts/just-kn… 🤖Open-source JAX ecosystem: github.com/patrick-kidger 🤿Scuba, sailing

◷ Joined July 2020▧ 147 Photos and videos
Patrick Kidger avatar
Patrick Kidger@PatrickKidger·8 Feb 2022

⚡️ My PhD thesis is on arXiv! ⚡️ To quote my examiners it is "the textbook of neural differential equations" - across ordinary/controlled/stochastic diffeqs. w/ unpublished material: - generalised adjoint methods - symbolic regression - + more! arxiv.org/abs/2202.02435 v🧵 1/n

Post attachmentPost attachment
Patrick Kidger avatar
Patrick Kidger@PatrickKidger·Nov 17

Iso did a $5B raise, okay, that's nice I guess. Where are the drugs? Iso promised the cure to all diseases. Five years and $7B+ further along, and Iso doesn't seem to have cured a single one?

So I have mixed feelings about IsoDDE. It's an AF4, it's much better on hard problems, and I don't want to understate their technical achievement. But also, it's been five years since founding, and success is measured in drugs, not models. Where are the drugs? 1/

Jack O'Meara avatar
⟳ Patrick Kidger retweeted
Jack O'Meara@Jack_O_Meara·Nov 14

Need better incentives. Regulatory/IP law should adapt to reward first-in-class biology. Target discovery is the noblest pursuit in pharma

need better target ID in addition to better molecular design

Jacob Kimmel avatar
⟳ Patrick Kidger retweeted
Jacob Kimmel@jacobkimmel·Nov 13

reversing this concentration is one of the great opportunities for our species in the coming years

77% of clinical-stage drugs go after the most popular 20% of targets, and 31% after the top 2%

Post attachment
Jack O'Meara avatar
⟳ Patrick Kidger retweeted
Jack O'Meara@Jack_O_Meara·Nov 12

Today we submitted our first FDA briefing book as a company. Onwards. 😊

Alexander Schubert avatar
⟳ Patrick Kidger retweeted
Alexander Schubert@alexschbrt·Nov 12

Biggest vacuum in biotech funding to me seems to be firms that can help put together meaningful Seed rounds. A lot of pre-seed and small Seed investors → Big vacuum → larger biotech investors that need to see a robust data package before coming in. Loads of very exciting technologies floating around, but the companies behind them lack the resources to really validate them. With the crazy advances in AI and bio infrastructure, I don't think these even need to be that big of a round -- think $10–15M could be quite transformative for many companies.

Alan Tomusiak avatar
⟳ Patrick Kidger retweeted
Alan Tomusiak@alantomusiak·Oct 30

Having started a biotech co in the past two years, the recent Mithril Medicine news felt pretty unsurprising. When people ask me what surprised me most about being a biotech founder, I always say that I dramatically overestimated the number of people I would need to hire. AI has been transformational here, but so has the excessive build-out of CRO capabilities in the COVID ZIRP era making CRO prices dramatically cheaper than they would be otherwise. Operations, chemistry, tox, and most preclinical work can all be outsourced for 20-60% of the price of building the same capabilities in house. The core platform still needs hands-on internal work, but if you're building a very traditional asset-flip biotech startup, then there is no core platform to begin with. There is some sacrifice in terms of speed over the long-term, but the combo of AI+automation+CROs suddenly allows biotech startups to create value on previously-challenging VC fund timelines. My prediction is that a biotech startup model consisting of a tiny team of 1-5 people is going to become fairly standard in the near-term future.

rico meinl avatar
⟳ Patrick Kidger retweeted
rico meinl@ricomnl·Oct 30

mfw >biology is just a data problem >collect enough omics, simulate the whole cell >read about humanin >peptide encoded inside the mitochondrial 16S rRNA gene >the same sequence is also a structural part of the ribosome >24 aa if the cytosol translates it, 21 aa if the mitochondria do >because mitochondria run a different genetic code >and start translation with N-formylmethionine instead of plain methionine >nobody's fully sure which one actually makes it >also 13 nuclear copies that might make their own versions >gets secreted into the blood >hits cell-surface receptors >one of them is literally a mitochondria detector >also gets taken back up >binds Bax inside the cell to block apoptosis >discovered by screening surviving brain tissue from an alzheimer's patient >open my cell model schema >compartment: yes >molecule_type: rRNA, peptide, hormone >length: depends who's asking

Patrick Kidger avatar
Patrick Kidger@PatrickKidger·Oct 27

Someone needs to raise $200M to launch cell-free (non-E. coli) GMP manufacture clearly the best way to make n=1 cancer treatments / any experimental low-batch-size stuff

💥 Introducing Warp Sciences, a new company applying AI and robotics to help the world develop new medicines faster. We’ve raised a $215M Series A led by @lightspeedvp to bring frontier AI out of the browser and into the lab, and build scientific capacity here in America. I co-founded Warp with my long-time friend @dpatil, FAIR co-founder @manohar_paluri, and drug hunter Sol Reisberg. The early team is full of incredible people like @bkspears9, who helped achieve Q>1 fusion at LLNL.

Patrick Kidger avatar
Patrick Kidger@PatrickKidger·Oct 25

Update: I've now *also* had multiple JAX-for-{fusion,molecular dynamics,...} companies ask me for referrals in the exact same way. I need to start hosting a job board haha

I've had [what feels like] approximately every AI+bio company ask me for any talent referrals recently. It's a seller's market right now. If you have at least a small portfolio (strong PhD or a couple years in industry) + are willing to work at least a 9-7 then you're golden. 1/2

Patrick Kidger avatar
Patrick Kidger@PatrickKidger·Oct 24

What the 'neopharma' discussion misses is that this is a class of companies, as "software" is a class. The VC pitch is the layer of detail below. Modality/in vivo data/etc. If you want to distinguish the serious/unserious, ask them what their GLP-tox strategy is.

A lot of this is just Stanford/ Valley money Like it's a bit inconsequential that these companies are AI x Bio. It's more of the fact that they are valley ppl. AI x Bio outside the valley or without deep Boston ties have no shot at raising this kind of money even if they're doing the same thing verbatim

Adam May avatar
⟳ Patrick Kidger retweeted
Adam May@A_May_MD·Oct 24

The degree of target clustering in pharma right now is absolute madness. How is this not objectively idiotic? The pendulum will swing back to unique/novel MoAs eventually…it just has to. Right now you can get VALIDATED novel/unique MoAs for less than some of these me-80 drugs in some cases. The system seems broken.

Insane; not enough patients for all these TSLP drugs. 😆 I saw there are 79 TSLP candidates but I guess it depends how broad you go and structure. There are no competitors with my R&D programs, to my knowledge.

Patrick Kidger avatar
Patrick Kidger@PatrickKidger·Oct 23

As usual, doing my bit to talk about bio topics in front of my AI audience: COINS (home.treasury.gov/news/press…) a possible rule to restrict US investments/JVs with Chinese biotech, released yesterday. My guess is that this will backfire the same way that the GPU blockade did: it will just result in a stronger competitor. And China's homegrown industry is already arguably the strongest (?) in the world. I don't have a stat for that, but it's noticeable from the ground: e.g. Chinese CROs actually respond to their emails same-day instead of next-week; WuXi clearly the market-leading biologics CDMO; etc.

Devan avatar
⟳ Patrick Kidger retweeted
Devan@dshahh·Oct 22

API for mRNA / nanoparticles here 👋🏽 w T cell activation data in vivo

Patrick Kidger avatar
Patrick Kidger@PatrickKidger·Oct 22

AI+bio: the Escalante folks released a blog post yesterday, and as usual it's a banger, talking more about their multiplexed protein binding assay: blog.escalante.bio/endless-p… (I imagine this got lost amidst the securitypocalypse that landed yesterday.)

Patrick Kidger avatar
Patrick Kidger@PatrickKidger·Oct 22

Great to see more API-for-biology companies out there (alongside Adaptyv, Biointron, Ginkgo, etc.) Warp looks chemistry-inflected (unlike a lot of the protein-focused ones we see). We still need more of this for the 'harder' properties: immunogenicity/T-cell activation, etc.

💥 Introducing Warp Sciences, a new company applying AI and robotics to help the world develop new medicines faster. We’ve raised a $215M Series A led by @lightspeedvp to bring frontier AI out of the browser and into the lab, and build scientific capacity here in America. I co-founded Warp with my long-time friend @dpatil, FAIR co-founder @manohar_paluri, and drug hunter Sol Reisberg. The early team is full of incredible people like @bkspears9, who helped achieve Q>1 fusion at LLNL.